Exercise in Improving Health and Quality of Life in Breast Cancer Survivors
Conditions:   Cancer Survivor;   Invasive Breast Carcinoma Interventions:   Other: Best Practice;   Behavioral: Exercise Intervention;   Other: Informational Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 20, 2018 Category: Research Source Type: clinical trials

Effect of Perioperative Low Dose Ketamine on Postoperative Recovery in Patients Undergoing Breast Cancer Surgery
Condition:   Breast Cancer Interventions:   Drug: ketamine;   Drug: Normal saline Sponsor:   Han Yuan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2018 Category: Research Source Type: clinical trials

Survival Endpoints for Treatment Evaluation in Subjects Treated for Metastatic Breast Cancer: Contribution of Real-life Databases
Condition:   Cancer Intervention:   Other: Endocrine therapies Sponsors:   Institut Bergonié;   UNICANCER;   Institut du Cancer de Montpellier, Montpellier, France Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2018 Category: Research Source Type: clinical trials

Effect of Perioperative Low Dose Ketamine on Postoperative Recovery in Patients Undergoing Breast Cancer Surgery
Condition:   Breast Cancer Interventions:   Drug: ketamine;   Drug: Normal saline Sponsor:   Han Yuan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2018 Category: Research Source Type: clinical trials

Survival Endpoints for Treatment Evaluation in Subjects Treated for Metastatic Breast Cancer: Contribution of Real-life Databases
Condition:   Cancer Intervention:   Other: Endocrine therapies Sponsors:   Institut Bergonié;   UNICANCER;   Institut du Cancer de Montpellier, Montpellier, France Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2018 Category: Research Source Type: clinical trials

Effect of Perioperative Low Dose Ketamine on Postoperative Recovery in Patients Undergoing Breast Cancer Surgery
Condition:   Breast Cancer Interventions:   Drug: ketamine;   Drug: Normal saline Sponsor:   Han Yuan Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2018 Category: Research Source Type: clinical trials

Study of Program Interest " Bouge " to Improve the Daily Physical Activity in Processings Treatment of Non-metastatic Breast Cancer
Conditions:   Physical Activity;   Breast Cancer;   Mobile Health Apps Interventions:   Device: Smartphone application  " placebo " ;   Device: Smartphone equipped with application " bouge " = Coach group Sponsor:   University Hospital, Brest Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Condition:   HER2-Positive Early Breast Cancer Interventions:   Drug: Pertuzumab and Trastuzumab FDC SC;   Drug: Pertuzumab IV;   Drug: Trastuzumab IV Sponsor:   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients
Condition:   Breast Cancer Intervention:   Other: Clinical outcomes Sponsor:   Jules Bordet Institute Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Condition:   HER2-Positive Early Breast Cancer Interventions:   Drug: Pertuzumab and Trastuzumab FDC SC;   Drug: Pertuzumab IV;   Drug: Trastuzumab IV Sponsor:   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

Study of Program Interest " Bouge " to Improve the Daily Physical Activity in Processings Treatment of Non-metastatic Breast Cancer
Conditions:   Physical Activity;   Breast Cancer;   Mobile Health Apps Interventions:   Device: Smartphone application  " placebo " ;   Device: Smartphone equipped with application " bouge " = Coach group Sponsor:   University Hospital, Brest Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients
Condition:   Breast Cancer Intervention:   Other: Clinical outcomes Sponsor:   Jules Bordet Institute Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Condition:   HER2-Positive Early Breast Cancer Interventions:   Drug: Pertuzumab and Trastuzumab FDC SC;   Drug: Pertuzumab IV;   Drug: Trastuzumab IV Sponsor:   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

Study of Program Interest " Bouge " to Improve the Daily Physical Activity in Processings Treatment of Non-metastatic Breast Cancer
Conditions:   Physical Activity;   Breast Cancer;   Mobile Health Apps Interventions:   Device: Smartphone application  " placebo " ;   Device: Smartphone equipped with application " bouge " = Coach group Sponsor:   University Hospital, Brest Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Condition:   HER2-Positive Early Breast Cancer Interventions:   Drug: Pertuzumab and Trastuzumab FDC SC;   Drug: Pertuzumab IV;   Drug: Trastuzumab IV Sponsor:   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients
Condition:   Breast Cancer Intervention:   Other: Clinical outcomes Sponsor:   Jules Bordet Institute Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

Study of Program Interest " Bouge " to Improve the Daily Physical Activity in Processings Treatment of Non-metastatic Breast Cancer
Conditions:   Physical Activity;   Breast Cancer;   Mobile Health Apps Interventions:   Device: Smartphone application  " placebo " ;   Device: Smartphone equipped with application " bouge " = Coach group Sponsor:   University Hospital, Brest Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Condition:   HER2-Positive Early Breast Cancer Interventions:   Drug: Pertuzumab and Trastuzumab FDC SC;   Drug: Pertuzumab IV;   Drug: Trastuzumab IV Sponsor:   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients
Condition:   Breast Cancer Intervention:   Other: Clinical outcomes Sponsor:   Jules Bordet Institute Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Condition:   Breast Cancer Interventions:   Drug: Ribociclib Placebo;   Drug: Ribociclib;   Drug: NSAI: Letrozole or Anastrazole;   Drug: Letrozole;   Drug: Goserelin Sponsor:   Novartis Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Condition:   Triple Negative Breast Cancer Interventions:   Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2);   Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2);   Drug: Taxotere® (100 mg/m2) Sponsors:   Jina Pharmaceuticals Inc.;   Intas Pharmaceuticals Limited;   Lambda Therapeutic Research Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Condition:   Breast Cancer Interventions:   Drug: Ribociclib Placebo;   Drug: Ribociclib;   Drug: NSAI: Letrozole or Anastrazole;   Drug: Letrozole;   Drug: Goserelin Sponsor:   Novartis Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Condition:   Triple Negative Breast Cancer Interventions:   Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2);   Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2);   Drug: Taxotere® (100 mg/m2) Sponsors:   Jina Pharmaceuticals Inc.;   Intas Pharmaceuticals Limited;   Lambda Therapeutic Research Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Condition:   Breast Cancer Interventions:   Drug: Ribociclib Placebo;   Drug: Ribociclib;   Drug: NSAI: Letrozole or Anastrazole;   Drug: Letrozole;   Drug: Goserelin Sponsor:   Novartis Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Condition:   Triple Negative Breast Cancer Interventions:   Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2);   Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2);   Drug: Taxotere® (100 mg/m2) Sponsors:   Jina Pharmaceuticals Inc.;   Intas Pharmaceuticals Limited;   Lambda Therapeutic Research Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Condition:   Breast Cancer Interventions:   Drug: Ribociclib Placebo;   Drug: Ribociclib;   Drug: NSAI: Letrozole or Anastrazole;   Drug: Letrozole;   Drug: Goserelin Sponsor:   Novartis Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Condition:   Triple Negative Breast Cancer Interventions:   Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2);   Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2);   Drug: Taxotere® (100 mg/m2) Sponsors:   Jina Pharmaceuticals Inc.;   Intas Pharmaceuticals Limited;   Lambda Therapeutic Research Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Condition:   Breast Cancer Interventions:   Drug: Ribociclib Placebo;   Drug: Ribociclib;   Drug: NSAI: Letrozole or Anastrazole;   Drug: Letrozole;   Drug: Goserelin Sponsor:   Novartis Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Condition:   Triple Negative Breast Cancer Interventions:   Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2);   Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2);   Drug: Taxotere® (100 mg/m2) Sponsors:   Jina Pharmaceuticals Inc.;   Intas Pharmaceuticals Limited;   Lambda Therapeutic Research Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Condition:   Breast Cancer Interventions:   Drug: Ribociclib Placebo;   Drug: Ribociclib;   Drug: NSAI: Letrozole or Anastrazole;   Drug: Letrozole;   Drug: Goserelin Sponsor:   Novartis Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Condition:   Triple Negative Breast Cancer Interventions:   Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2);   Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2);   Drug: Taxotere® (100 mg/m2) Sponsors:   Jina Pharmaceuticals Inc.;   Intas Pharmaceuticals Limited;   Lambda Therapeutic Research Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2018 Category: Research Source Type: clinical trials

Estudy of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer
Condition:   Outcome of Breast Cancer Intervention:   Other: None intervention Sponsor:   Omphis Foundation Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2018 Category: Research Source Type: clinical trials

No Axillary Surgery for Early Breast Cancer.
Condition:   Breast Cancer Invasive Intervention:   Procedure: Omitting axillary surgery in early breast cancer Sponsors:   Lund University;   Swedish Breast Cancer Group Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2018 Category: Research Source Type: clinical trials

Hypo-Fractionated Radiotherapy in Breast Cancer
Conditions:   Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer Intervention:   Radiation: Hypo fractionated whole breast radiotherapy Sponsor:   Tata Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2018 Category: Research Source Type: clinical trials

No Axillary Surgery for Early Breast Cancer.
Condition:   Breast Cancer Invasive Intervention:   Procedure: Omitting axillary surgery in early breast cancer Sponsors:   Lund University;   Swedish Breast Cancer Group Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2018 Category: Research Source Type: clinical trials

Estudy of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer
Condition:   Outcome of Breast Cancer Intervention:   Other: None intervention Sponsor:   Omphis Foundation Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2018 Category: Research Source Type: clinical trials

Hypo-Fractionated Radiotherapy in Breast Cancer
Conditions:   Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer Intervention:   Radiation: Hypo fractionated whole breast radiotherapy Sponsor:   Tata Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2018 Category: Research Source Type: clinical trials

No Axillary Surgery for Early Breast Cancer.
Condition:   Breast Cancer Invasive Intervention:   Procedure: Omitting axillary surgery in early breast cancer Sponsors:   Lund University;   Swedish Breast Cancer Group Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2018 Category: Research Source Type: clinical trials

Estudy of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer
Condition:   Outcome of Breast Cancer Intervention:   Other: None intervention Sponsor:   Omphis Foundation Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2018 Category: Research Source Type: clinical trials